Thus, the addition of both ASA and low-dose IL-2 to the OCDC-Bev-Cy combinatorial regimen induced a Th1-polarizing sera chemokine profile, particularly CXCL9 that was conducive for the recruitment of CD3+ and CD8+ TILs for tumor control. This evidence concerns the gene CXCL9 and neoplasm.